A cancer-test story running against the clock

Oxford BioDynamics Plc (LSE/AIM: OBD) has a genuine scientific asset and an acute financial problem, and its interim results on 30 June 2026 put both on display. Sales of its flagship prostate blood test are climbing fast, a new chief executive from the genomics industry has arrived, and its research platform is drawing pharmaceutical interest. At the same time, the company's own auditors and board flag "material uncertainty" over its ability to continue as a going concern, with cash forecast to run short by late August 2026. This is a company advancing its technology while simultaneously fighting for survival.

Company overview and the EpiSwitch platform

Oxford BioDynamics is a UK clinical-diagnostics company built on "epigenetics" — the study of how genes are switched on or off without changing the underlying DNA sequence. Its EpiSwitch platform measures the three-dimensional folding of chromosomes (how DNA loops physically fold in the cell nucleus), using these structural patterns as "biomarkers" — measurable biological signals that indicate disease or predict how a patient will respond to treatment.

The commercial products are blood tests. The lead product, PSE (Prostate Screening EpiSwitch), aims to reduce unnecessary prostate biopsies by improving on the standard PSA test. A second test, CiRT (Checkpoint Inhibitor Response Test), predicts whether cancer patients will respond to "checkpoint inhibitors" — immunotherapy drugs that release the brakes on the immune system so it can attack tumours. In March 2026 the group also launched EpiSwitch Orion, a cloud-based research platform selling 3D-genomic analysis to drug developers.

The latest announcement in detail

The 30 June 2026 interim results (covering the six months to 31 March 2026) are the material catalyst. The headline operational fact is PSE momentum: 1,788 PSE tests were sold in H1 2026, up 66% on the prior half and 126% on the same period a year earlier (H1 2025). Cumulatively, more than 5,000 PSE tests have been sold since the September 2023 US launch — modest in absolute terms, but a clear acceleration.

Alongside results, the board announced two other items on the same morning: the appointment of Richard Compton as chief executive, and a US contract-sales partnership with MK Commercial Group that management says lifts field-sales presence by around 60%. Compton joined from Oxford Nanopore Technologies, where he was senior vice-president of sales and commercial operations during its growth from roughly £4m to over £200m of revenue; he previously worked at Illumina. His stated priority is a "more focused, scalable and commercially disciplined business" — language that signals cost restraint as much as expansion.

The CEO hire is a credible commercial signal, but a new leader does not by itself close a funding gap. The market response has been muted — shares remain sub-penny.

Latest financials

For H1 2026, revenue was £0.69m, up from £0.59m a year earlier. The operating loss narrowed to £4.68m from £5.88m, and the net loss for the period was £4.46m. Revenue growth is real but from a very low base, and the company remains deeply loss-making, with losses running at many multiples of sales.

Balance sheet, liquidity and cash runway

This is the crux. Cash stood at £2.51m at 31 March 2026, but had already fallen to £1.38m by 31 May 2026 — implying a burn of well over £0.5m a month. The company states it requires additional funds by late August 2026 and that the board forecasts a need for a minimum of £3m of equity funding during calendar Q3 2026. The accounts carry the explicit warning of "material uncertainty which may cast significant doubt on the Group's ability to continue as a going concern."

Crucially, this follows a history of repeated dilution. A November 2025 equity placing raised £6.32m net (£7m gross); a January 2025 retail offer was priced at just 0.5 pence. With roughly 4.29 billion shares now in issue, further equity issuance at depressed prices would dilute existing holders heavily. As of 24–25 July 2026 the shares traded at about 0.125 pence, for a market capitalisation near £5.36m, against a 52-week range of 0.085p (2 July 2026) to 0.675p (8 October 2025) — a fall of roughly 73% over the year.

Operational and commercial progress

Beyond PSE, the pipeline is broadening. A ME/CFS (chronic fatigue syndrome) blood test was announced in October 2025 and remains in validation. EpiSwitch Orion, launched March 2026, is in use by research institutions, with the company reporting commercial discussions with three large pharmaceutical companies — though discussions are not signed contracts. Notably, CiRT sales have been restricted pending an application for inclusion in NCCN (National Comprehensive Cancer Network) guidelines; guideline inclusion is important because it drives clinician adoption and reimbursement, but the outcome and timing are uncertain.

Externally, the PSE test has featured in peer-reviewed clinical-utility work — including a 2025 study in the journal Cancers on reducing unnecessary biopsies — and is being used in correlative studies within a US National Cancer Institute trial. These support the science but are not, in themselves, revenue.

Diagnostics-market context

Oxford BioDynamics operates in the fast-growing liquid-biopsy and molecular-diagnostics market, where blood-based tests promise earlier, less invasive cancer detection. The opportunity is large, but so is the challenge: commercial success hinges on clinical-guideline inclusion, payer reimbursement and physician adoption — a slow, capital-intensive path that has strained many well-funded diagnostics peers. OBD is attempting this as a micro-cap with minimal cash.

Growth catalysts

Watch for: completion of the required Q3 2026 fundraising and its terms; any NCCN decision affecting CiRT; conversion of the three pharma Orion discussions into signed deals; continued PSE volume growth and evidence the MK Commercial partnership is working; and progress on the ME/CFS test validation.

Principal risks and warning signs

The dominant risk is financing and dilution. The going-concern warning is explicit; if the £3m-plus raise is not completed on time, the company's ability to continue trading is in doubt. Even a successful raise at current sub-penny levels would be highly dilutive. Other risks: reliance on a small revenue base; dependence on guideline/reimbursement decisions outside the company's control; execution risk under new leadership; and the general fragility of loss-making micro-caps. The 52-week low set on 2 July 2026 — just after results — underlines market scepticism.

Balanced investor considerations

On the positive side, PSE volumes are accelerating, the loss is narrowing, the platform has peer-reviewed clinical support and pharma interest, and a commercially experienced CEO is now in charge. On the negative side, absolute revenue remains tiny, cash is nearly exhausted, and the survival of the business depends on raising fresh, dilutive equity within weeks. This is a binary, high-risk situation rather than a steady growth story.

Conclusion

The verifiable evidence supports a nuanced picture: OBD's cancer-test platform is genuinely advancing — 126% PSE sales growth and a credible new CEO are facts, not spin — but the "next big leap" is overshadowed by a near-term liquidity cliff. The company itself says it needs a minimum £3m by Q3 2026, with cash only into late August, under a formal going-concern warning. Whether OBD secures that funding, and on what dilutive terms, is the decisive question for shareholders.

Key Takeaways

  • PSE prostate-test sales rose 126% year-on-year in H1 2026 (1,788 tests; >5,000 since the 2023 US launch), and diagnostics veteran Richard Compton was appointed CEO on 30 June 2026.
  • Despite the narrower operating loss (£4.68m) and revenue of £0.69m, cash fell to £1.38m by 31 May 2026; the board carries a going-concern warning and needs a minimum £3m of equity in Q3 2026, with funds required by late August.
  • Shares trade around 0.125p (mid-to-late July 2026), down ~73% over a year, with ~4.29bn shares in issue — further fundraising would be heavily dilutive.